Avricore HealthAVCRF +19.18% Days Payable is 471.46 as of Mar. 2026, which is 78% above its 10-year median of 264.50. The stock has 6 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Avricore Health ranks better than 82.11% on this metric.
The historical rank and industry rank for Avricore Health's Days Payable or its related term are showing as below:
AVCRF'
s Days Payable Range Over the Past 10 Years
Min: 42.46 Med: 264.5 Max: 8577.5
Current: 217.88
During the past 13 years, Avricore Health's highest Days Payable was 8577.50. The lowest was 42.46. And the median was 264.50.
AVCRF's Days Payable is ranked better than 82.11% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs AVCRF: 217.88
Avricore Health's Days Payable
increased
from Mar. 2025 (209.43) to Mar. 2026 (471.46).
It may suggest that Avricore Healthdelayed paying its suppliers.
Avricore Health Days Payable Related Terms
Avricore Health Days Payable Historical Data
* Premium members only.
The historical data trend for Avricore Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Avricore Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avricore Health Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Avricore Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Avricore Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Avricore Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avricore Health (AVCRF) has a Days Payable of 471.46 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Avricore Health and its competitors. This is 78% above median its historical median of 264.50. Over the past decade, Avricore Health's Days Payable has ranged from 42.46 to 8,577.50. According to the industry distribution chart, Avricore Health ranks #34 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 17.9%.
Is Avricore Health's Days Payable too high?
Avricore Health's current Days Payable of 471.46 is 78% above median its 10-year median of 264.50. Over the past 10 years, this metric has ranged from a low of 42.46 to a high of 8,577.50. The Medical Diagnostics & Research industry median Days Payable is 67.28. Avricore Health's value of 471.46 is 600.8% above this industry median. Based on the distribution chart, Avricore Health ranks #34 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Avricore Health's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Avricore Health ranks #34 out of 190 companies for Days Payable. This places Avricore Health in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.28. Avricore Health's value of 471.46 is 600.8% above this benchmark. Historically, Avricore Health's own Days Payable has ranged from 42.46 to 8,577.50 over the past decade. While the company's 10-year median is 264.50 vs. the industry median of 67.28, Avricore Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avricore Health's current Days Payable of 471.46 is 600.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Avricore Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avricore Health's current Days Payable is 471.46, which is 78% above median its own 10-year median of 264.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avricore Health stock overvalued right now?
Based on GuruFocus' analysis, Avricore Health (AVCRF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.04 — trading 95.9% above its estimated fair value. The current Days Payable is 471.46, which is 78% above median its 10-year median of 264.50 and 600.8% above the Medical Diagnostics & Research industry median of 67.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Avricore Health (AVCRF), the current Days Payable is 471.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avricore Health Inc is a Canada-based company. The company is involved in the business of health data and point-of-care technologies. The company has only one segment, being the HealthTab - Point of Care Business in Canada. The company's revenues are generated from operating leases of the POCT system and the sale of testing panels. Geographically, the company operates in Canada and United Kingdom, it derives maximum revenue Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCRF has been successfully added to your 